Abstract
The levels of serum beta 2 microglobulin, blood urea concentration, serum creatinine, haemoglobin and performance status have been measured in 476 patients in the Medical Research Council's 4th trial for myelomatosis. Levels of serum beta 2 microglobulin were also subsequently measured in 208 patients who achieved a stable "plateau" condition. Serum beta 2 microglobulin levels, uncorrected for serum creatinine, were found to be the single most powerful prognostic variable available at presentation. Multivariate analysis showed that only the addition of haemoglobin levels could improve upon this and the improvement, though statistically significant (P = 0.006), appeared to be of much less clinical value. The prognostic value of serum beta 2 microglobulin at plateau appeared to be equally large for a given difference in value, but the variability between patients was much less at that time. Serum beta 2 microglobulin would appear to be a key measurement for assessing the prognosis and response to treatment in patients with myelomatosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Cuzick, J., Cooper, E. & MacLennan, I. The prognostic value of serum β 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 52, 1–6 (1985). https://doi.org/10.1038/bjc.1985.140
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.140
This article is cited by
-
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
Molecular Cancer (2023)
-
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy
Targeted Oncology (2021)
-
Prognostic factors and their correlation with staging in patients with multiple myeloma: a single centre study in North India
memo - Magazine of European Medical Oncology (2015)